BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19033664)

  • 1. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.
    Hui L; Zatloukal K; Scheuch H; Stepniak E; Wagner EF
    J Clin Invest; 2008 Dec; 118(12):3943-53. PubMed ID: 19033664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
    Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
    Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
    Sakurai T; Maeda S; Chang L; Karin M
    Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10544-51. PubMed ID: 16807293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    Cubero FJ; Zhao G; Nevzorova YA; Hatting M; Al Masaoudi M; Verdier J; Peng J; Schaefer FM; Hermanns N; Boekschoten MV; Grouls C; Gassler N; Kiessling F; Muller M; Davis RJ; Liedtke C; Trautwein C
    J Hepatol; 2015 Jan; 62(1):140-9. PubMed ID: 25173965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JNK in the development of hepatocellular carcinoma.
    Das M; Garlick DS; Greiner DL; Davis RJ
    Genes Dev; 2011 Mar; 25(6):634-45. PubMed ID: 21406557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
    Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
    Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury.
    Marhenke S; Buitrago-Molina LE; Endig J; Orlik J; Schweitzer N; Klett S; Longerich T; Geffers R; Sánchez Muñoz A; Dorrell C; Katz SF; Lechel A; Weng H; Krech T; Lehmann U; Dooley S; Rudolph KL; Manns MP; Vogel A
    Gut; 2014 Sep; 63(9):1501-12. PubMed ID: 24092862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
    Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
    Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
    Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
    Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte.
    Udden SN; Kwak YT; Godfrey V; Khan MAW; Khan S; Loof N; Peng L; Zhu H; Zaki H
    Elife; 2019 Apr; 8():. PubMed ID: 30990169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.
    Yeganeh M; Gui Y; Kandhi R; Bobbala D; Tobelaim WS; Saucier C; Yoshimura A; Ferbeyre G; Ramanathan S; Ilangumaran S
    Oncogene; 2016 Aug; 35(32):4200-11. PubMed ID: 26725321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.
    Kodama Y; Taura K; Miura K; Schnabl B; Osawa Y; Brenner DA
    Gastroenterology; 2009 Apr; 136(4):1423-34. PubMed ID: 19249395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
    Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
    Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the JNK activation in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells.
    Hsu SP; Ho PY; Liang YC; Ho YS; Lee WS
    J Cell Biochem; 2009 Nov; 108(4):860-6. PubMed ID: 19693773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
    Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
    Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
    Chang Q; Zhang Y; Beezhold KJ; Bhatia D; Zhao H; Chen J; Castranova V; Shi X; Chen F
    J Hepatol; 2009 Feb; 50(2):323-33. PubMed ID: 19041150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
    Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
    Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway.
    Zhang Y; Liu Y; Duan J; Yan H; Zhang J; Zhang H; Fan Q; Luo F; Yan G; Qiao K; Liu J
    Hepatology; 2016 Mar; 63(3):880-97. PubMed ID: 26659654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STK33 promotes hepatocellular carcinoma through binding to c-Myc.
    Yang T; Song B; Zhang J; Yang GS; Zhang H; Yu WF; Wu MC; Lu JH; Shen F
    Gut; 2016 Jan; 65(1):124-33. PubMed ID: 25398772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.